The pandemic continues to cause unprecedented disruption across industries worldwide.
Get detailed insights regarding the impact of COVID-19 on the market.
The global medical footwear market grew at a CAGR of around 7% during 2015-2020. Looking forward, IMARC Group expects the market to exhibit moderate growth during 2021-2026. Keeping in mind the uncertainties of COVID-19, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic. These insights are included in the report as a major market contributor.
Medical footwear refers to specially designed footwear that assists in the treatment of various foot-related medical ailments. Some of these health conditions include arthritis, plantar fasciitis, bunions and hallux valgus, and Achilles tendonitis. It is also being utilized by individuals with flat feet and diabetes. Wearing it on a regular basis ensures proper blood circulation in the users’ body while offering enhanced support to their feet. These shoes can be customized as well to meet the specific requirements of the customer.
The market is primarily driven by the rising incidences of foot-related conditions. Medical issues, including foot and ankle injuries, corns, flat feet and arthritis, have impelled the masses to invest in good-quality medical footwear that provides a cushion to the entire foot while promoting mobility, support and healthy blood circulation. Along with this, increasing foot care awareness among individuals is expected to facilitate the uptake of these shoes. The market is further driven by the increasing prevalence of diabetes across the globe. Poorly controlled blood sugar levels among patients can often damage the nerves and vessels present in the legs and feet, resulting in the development of peripheral neuropathy. This condition is characterized by tingling sensation, numbness, muscle weakness and pain in the affected area. As a result, diabetic patients increasingly prefer the use of medical footwear to prevent the development of neuropathy or provide support to their ankle and foot in case of its onset. Some of the other factors contributing to the market growth include the increased consumer spending and the easy product availability through various pharmacies and online retail channels.
IMARC Group provides an analysis of the key trends in each sub-segment of the global medical footwear market, along with forecasts at the global, regional and country level from 2021-2026. Our report has categorized the market based on end user and distribution channel.
Breakup by End User:
Breakup by Distribution Channel:
Breakup by Region:
The competitive landscape of the industry has also been examined along with the profiles of the key players being Aetrex Worldwide Inc., Darco International Inc. (Wright Medical Group N.V.), Djo LLC (Colfax Corporation), Dr. Foot Inc., Dr. Zen Inc., Drewshoe Incorporated, Duna Srl, Gravity Defyer Corp., Horng Shin Footwear Co., Mephisto S.A.S, New Balance Inc., Orthofeet Inc. and Podartis srl.
|Base Year of the Analysis||2020|
|Segment Coverage||End User, Distribution Channel, Region|
|Region Covered||Asia Pacific, Europe, North America, Latin America, Middle East and Africa|
|Countries Covered||United States, Canada, Germany, France, United Kingdom, Italy, Spain, Russia, China, Japan, India, South Korea, Australia, Indonesia, Brazil, Mexico|
|Companies Covered||Aetrex Worldwide Inc., Darco International Inc. (Wright Medical Group N.V.), Djo LLC (Colfax Corporation), Dr. Foot Inc., Dr. Zen Inc., Drewshoe Incorporated, Duna Srl, Gravity Defyer Corp., Horng Shin Footwear Co., Mephisto S.A.S, New Balance Inc., Orthofeet Inc. and Podartis srl|
|Customization Scope||10% Free Customization|
|Report Price and Purchase Option||Single User License: US$ 2299
Five User License: US$ 3399
Corporate License: US$ 4499
|Post-Sale Analyst Support||10-12 Weeks|
|Delivery Format||PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request)|
REACH OUT TO US
Call us on
( US: +1-631-791-1145 )
( UK: +44-753-713-2163 )
( India: +91 120 433 0800 )
Drop us an email at